Perez Irving E, Taveras Alam Sara, Hernandez Gabriel A, Sancassani Rhea
Department of Cardiovascular Disease, Jackson Memorial Hospital, University of Miami Hospital, Miami, FL, USA.
Section of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Clin Med Insights Cardiol. 2019 Jul 29;13:1179546819866445. doi: 10.1177/1179546819866445. eCollection 2019.
Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.
癌症治疗相关的心脏功能障碍（CTRCD）是化疗最可怕且不良的副作用之一，约10%的患者会出现。它可分为直接（剂量依赖性与剂量非依赖性）或间接的，两种情况都可能是永久性或可逆性的。CTRCD的风险评估、识别和预防至关重要。
